Bharat Parenterals Ltd.
Snapshot View

374.90 +4.80 ▲1.3%

26 July 2021, 04:00:00 P.M.
Volume: 703

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.bplindia.in
Financial Indicators
Market Cap 214.81 Cr.
Earnings per share (EPS) 35.59 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 10.53 Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share 251.01 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.49 Calculated using Price: 374.90
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.57 Cr. 5,729,666 Shares
FaceValue 10
Company Profile

Bharat Parenterals was formed under the chairmanship of Ramesh Desai and incorporated as limited company on September 3, 1992. The company has grown steadily from a humble beginning, to a position of strength under the stewardship of Bharat R. Desai, a visionary whose untiring patience, perseverance & unflinching commitment has resulted in the growth of the company. He has effectively combined his tact & talent, business acumen & professional experience in the pharmaceutical field to bring the company in the forefront of contract manufacturing units in Gujarat. Besides, the company has established its own range of products in domestic & international markets. The company has added a feather in the cap by setting up a dedicated facility for antiretroviral drugs to its existing facility of general & B-Iactum group of drugs.

The company has established its own range of products in domestic & international markets. Its main vision is commited to become a major pharmaceutical company catering to domestic and international market by manufacturing and marketing high quality Pharmaceutical Formulation meeting all customer & regulatory requirements. 

Business area of the company:

The company is engaged in to the business of the Pharmaceuticals & Drugs.

Products:

GENERAL:

- Tablets 

- Capsules

- Injections

- Oral Liquids 

 - Dry Syrups

- External Preparations

- ENT

- Sachets 

- Granules

LACTAM:

- Tablets 

- Capsules 

- Injections 

- Dry Syrups

CEPHALOSPORINS:

- Tablets  

- Capsules

- Injections 

- Dry Syrups

 - Sachets

ANTIRETROVIRAL:

- Tablets

- Capsules 

- Oral Liquids

VETERINARY:

- Tablets

- Injections 

- Oral Liquids

- Semi Solids

Subsidiaries:

Varenyam (A division of Bharat Parenterals).

The company was formed under the chairmanship of Mr. Bharat Desai and incorporated as Private Limited company on 9th July 2016.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+1.30%
1 Week
-0.11%
1 Month
+1.41%
3 Month
-8.15%
6 Month
-0.39%
1 Year
-10.71%
2 Year
+105.76%
5 Year
5 years 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 11.38 11.45 13.35 25.47 22.76
Return on Capital Employed (%) 14.23 11.47 18.10 39.30 30.83
Return on Assets (%) 5.37 5.99 7.61 14.71 13.94

Balance Sheet View Details

Particulars 5 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 57 64 73 94 118
Non Curr. Liab. 7 3 0 4 3
Curr. Liab. 56 43 57 61 66
Minority Int.
Equity & Liab. 120 110 130 159 188
Non Curr. Assets 49 46 39 41 56
Curr. Assets 72 64 91 118 132
Misc. Exp. not W/O
Total Assets 120 110 130 159 188

Profit Loss View Details

Particulars 5 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 124 111 137 220 228
Other Income 5 8 7 13 12
Total Income 129 119 144 232 240
Total Expenditure -114 -105 -124 -191 -201
PBIDT 15 14 19 42 40
Interest -1 -1 -1 -1 -1
Depreciation -4 -6 -6 -6 -6
Taxation -3 -1 -4 -13 -9
Exceptional Items
PAT 6 7 9 21 24

Cash Flow View Details

Particulars 5 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. -2 6 20 14
Cash Fr. Inv. -2 -8 -9 -13
Cash Fr. Finan. -8 4 -4 -3
Net Change -11 2 7 -1
Cash & Cash Eqvt 2 4 11 10

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 74.42 74.42 74.42 74.42 74.42 74.42 74.42 74.42 74.42
Public 25.58 25.58 25.58 25.58 25.58 25.58 25.58 25.58 25.58
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Sat, 24 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we bring to your kind attention that the Company/RTA has received a request from the shareholder regarding loss of her Share certificates. In this regard Adroit Corporate Services Private Limited RTA of company has verified the details and had informed the shareholder the necessary procedure for issue of duplicate share certificates. After receipt of valid documents the Share certificates will be issued within the statutory time limit.
Mon, 19 Jul 2021
Shareholding for the Period Ended June 30 2021
Bharat Parenterals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Mon, 12 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- LUBHANSHI JHALANI
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Mon, 26 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index
Both SRS And ARS Below Zero Both SRS And ARS Below Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%